Peter Lynch fit · Growth at a reasonable price (GARP)
Is Acadia Pharmaceuticals Inc. (ACAD) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
15/100
FNão encaixa
3/6 critérios atendidos
Os critérios de Peter Lynch, aplicados a ACAD
PEG ≤ 1.0
chave—
EPS CAGR ≥ 15%
chave0.0%
Revenue CAGR ≥ 10%
-22.5%
Net margin > 0
24.9%
Como ACAD pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$4.65B
P/L (TTM)
19.0x
ROIC (TTM)
25.22%
Margem bruta
91.92%
Perguntas frequentes
What is ACAD's Peter Lynch fit score?
ACAD scores 15/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own ACAD?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ACAD.
How often is this score updated?
ACAD's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Peter Lynch possua ou recomende ACAD pessoalmente.